Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 76

1.

Serotonergic Approaches in Parkinson's Disease: Translational Perspectives, an Update.

Huot P, Sgambato-Faure V, Fox SH, McCreary AC.

ACS Chem Neurosci. 2017 May 17;8(5):973-986. doi: 10.1021/acschemneuro.6b00440. Epub 2017 May 5.

PMID:
28460160
2.

Frequency-Dependent Modulation of Dopamine Release by Nicotine and Dopamine D1 Receptor Ligands: An In Vitro Fast Cyclic Voltammetry Study in Rat Striatum.

Goutier W, Lowry JP, McCreary AC, O'Connor JJ.

Neurochem Res. 2016 May;41(5):945-50. doi: 10.1007/s11064-015-1786-8. Epub 2016 Mar 15.

PMID:
26975318
3.

The novel 5-HT1A receptor agonist, NLX-112 reduces l-DOPA-induced abnormal involuntary movements in rat: A chronic administration study with microdialysis measurements.

McCreary AC, Varney MA, Newman-Tancredi A.

Neuropharmacology. 2016 Jun;105:651-660. doi: 10.1016/j.neuropharm.2016.01.013. Epub 2016 Jan 9.

PMID:
26777281
4.

Psychostimulants: Basic and Clinical Pharmacology.

McCreary AC, Müller CP, Filip M.

Int Rev Neurobiol. 2015;120:41-83. doi: 10.1016/bs.irn.2015.02.008. Epub 2015 Mar 25. Review.

PMID:
26070753
5.

Serotonin 5-HT1A Receptors and Antipsychotics - An Update in Light of New Concepts and Drugs.

McCreary AC, Newman-Tancredi A.

Curr Pharm Des. 2015;21(26):3725-31. Review.

PMID:
26044980
6.

NLX-112, a novel 5-HT1A receptor agonist for the treatment of L-DOPA-induced dyskinesia: Behavioral and neurochemical profile in rat.

Iderberg H, McCreary AC, Varney MA, Kleven MS, Koek W, Bardin L, Depoortère R, Cenci MA, Newman-Tancredi A.

Exp Neurol. 2015 Sep;271:335-50. doi: 10.1016/j.expneurol.2015.05.021. Epub 2015 May 30.

PMID:
26037043
7.

Discovering the mechanisms underlying serotonin (5-HT)2A and 5-HT2C receptor regulation following nicotine withdrawal in rats.

Zaniewska M, Alenina N, Wydra K, Fröhler S, Kuśmider M, McCreary AC, Chen W, Bader M, Filip M.

J Neurochem. 2015 Aug;134(4):704-16. doi: 10.1111/jnc.13192. Epub 2015 Jun 26.

8.

Context-controlled nicotine-induced changes in the labeling of serotonin (5-HT)2A and 5-HT2C receptors in the rat brain.

Zaniewska M, McCreary AC, Wydra K, Faron-Górecka A, Filip M.

Pharmacol Rep. 2015 Jun;67(3):451-9. doi: 10.1016/j.pharep.2014.11.002. Epub 2014 Nov 24.

PMID:
25933953
9.

The effect of nicotine induced behavioral sensitization on dopamine D1 receptor pharmacology: An in vivo and ex vivo study in the rat.

Goutier W, O'Connor JJ, Lowry JP, McCreary AC.

Eur Neuropsychopharmacol. 2015 Jun;25(6):933-43. doi: 10.1016/j.euroneuro.2015.02.008. Epub 2015 Mar 3.

PMID:
25795518
10.

Activity of serotonin 5-HT(1A) receptor 'biased agonists' in rat models of Parkinson's disease and L-DOPA-induced dyskinesia.

Iderberg H, McCreary AC, Varney MA, Cenci MA, Newman-Tancredi A.

Neuropharmacology. 2015 Jun;93:52-67. doi: 10.1016/j.neuropharm.2015.01.012. Epub 2015 Jan 31.

PMID:
25645393
11.

Nicotine-induced locomotor sensitization: pharmacological analyses with candidate smoking cessation aids.

Goutier W, Kloeze M, McCreary AC.

Addict Biol. 2016 Mar;21(2):234-41. doi: 10.1111/adb.12190. Epub 2014 Oct 13.

PMID:
25307867
12.

The H3 receptor agonist immepip does not affect l-dopa-induced abnormal involuntary movements in 6-OHDA-lesioned rats.

Papathanou M, Jenner P, Iravani M, Jackson M, Stockwell K, Strang I, Zeng BY, McCreary AC, Rose S.

Eur J Pharmacol. 2014 Oct 15;741:304-10. doi: 10.1016/j.ejphar.2014.08.004. Epub 2014 Aug 23.

PMID:
25160743
13.

Striatal serotonin 2C receptors decrease nigrostriatal dopamine release by increasing GABA-A receptor tone in the substantia nigra.

Burke MV, Nocjar C, Sonneborn AJ, McCreary AC, Pehek EA.

J Neurochem. 2014 Nov;131(4):432-43. doi: 10.1111/jnc.12842. Epub 2014 Aug 21.

14.

The effect of varenicline on the development and expression of nicotine-induced behavioral sensitization and cross-sensitization in rats.

Goutier W, Kloeze MB, McCreary AC.

Addict Biol. 2015 Mar;20(2):248-58. doi: 10.1111/adb.12108. Epub 2013 Nov 20.

PMID:
24251901
15.

Serotonin2C receptors and drug addiction: focus on cocaine.

Devroye C, Filip M, Przegaliński E, McCreary AC, Spampinato U.

Exp Brain Res. 2013 Oct;230(4):537-45. doi: 10.1007/s00221-013-3593-2. Epub 2013 Jun 8. Review.

PMID:
23748692
16.

Effects of the histamine H₃ receptor antagonist ABT-239 on cognition and nicotine-induced memory enhancement in mice.

Kruk M, Miszkiel J, McCreary AC, Przegaliński E, Filip M, Biała G.

Pharmacol Rep. 2012;64(6):1316-25.

17.

Levodopa infusion does not decrease the onset of abnormal involuntary movements in parkinsonian rats.

Papathanou M, van der Laan R, Jenner P, Rose S, McCreary AC.

Mov Disord. 2013 Jul;28(8):1072-9. doi: 10.1002/mds.25218. Epub 2012 Nov 2.

PMID:
23125107
18.

A novel highly selective 5-HT6 receptor antagonist attenuates ethanol and nicotine seeking but does not affect inhibitory response control in Wistar rats.

de Bruin NM, McCreary AC, van Loevezijn A, de Vries TJ, Venhorst J, van Drimmelen M, Kruse CG.

Behav Brain Res. 2013 Jan 1;236(1):157-65. doi: 10.1016/j.bbr.2012.08.048. Epub 2012 Sep 4.

PMID:
22974550
19.

Assessment of ropinirole as a reinforcer in rhesus monkeys.

Freeman KB, Heal DJ, McCreary AC, Woolverton WL.

Drug Alcohol Depend. 2012 Sep 1;125(1-2):173-7. doi: 10.1016/j.drugalcdep.2012.04.001. Epub 2012 Apr 28.

PMID:
22546848
20.

Pharmacological and genetic interventions in serotonin (5-HT)(2C) receptors to alter drug abuse and dependence processes.

Filip M, Spampinato U, McCreary AC, Przegaliński E.

Brain Res. 2012 Oct 2;1476:132-53. doi: 10.1016/j.brainres.2012.03.035. Epub 2012 Mar 23. Review.

PMID:
22494568

Supplemental Content

Loading ...
Support Center